Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

nippon

Lilly links up with Precision BioSciences in genome editing deal

Lilly links up with Precision BioSciences in genome editing deal

In August, the US Food and Drug Administration (FDA) approved Japanese pharmaceutical company  Nippon Shinyaku’s (NS Pharma) DMD drug Viltepso (viltolarsen).

FDA approves Sarepta rival NS Pharma’s Duchenne drug

FDA approves Sarepta rival NS Pharma’s Duchenne drug Drug approved for patients with exon 53 mutation. Japanese pharma Nippon Shinyaku (NS Pharma) has scored US Food and Drug Administration (FDA) approval for its Duchenne muscular dystrophy drug viltolarsen, now

FDA sets Q3 decision date for NS Pharma’s DMD drug

FDA sets Q3 decision date for NS Pharma’s DMD drug NS Pharma and its parent company Nippon Shinyaku are currently enrolling patients for a phase 3 study in Japan and the US – named RACER53.

Wave’s challenge to Sarepta in Duchenne falls flat

Wave’s challenge to Sarepta in Duchenne falls flat The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD.

Solid Bio falls as FDA halts DMD trial over safety concerns

Solid Bio falls as FDA halts DMD trial over safety concerns In the meantime, rival candidate viltolarsen from Japanese pharma Nippon Shinyaku (NS Pharma) has been  filed with the FDA for the treatment of DMD.

1 2 3 4 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...